Tag: Coronavirus

CRISPR Gene Editing: A Solution to Address COVID-19

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, coronavirus preventive vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19.

Collaborative Robotics Helping in Pandemic Management?

With the new threat to humanity presented by Pandemic COVID-19, another bigger challenges for the pharmaceutical industries are bulk vaccine production in the limited time span. How will the pharma sector be going to cope with these challenges? Well, lab automation has always improved the quality and efficiency of the production process in the pharmaceutical

Prefilled Syringe: Impact on COVID 19 and Vaccines

Coronavirus(COVID 19) is spreading around the world, with 2.6 million global active cases. Till date, there are no approved treatments for COVID-19. However, multiple pharmaceutical companies are doing research at breakneck speed to develop therapeutics and coronavirus preventive vaccines against this novel virus. The pharma industry is hoping to compress the development timelines to get

COVID-19: Where are we today?

Comparison with other communicable diseases According to worldometers.info, as of 5 April 2020 (5:30 PM GMT), the total number of COVID-19 cases rose to over a million, with a reported mortality rate of 5%. Further, a comparison with certain other communicable disease-related deaths (Figure below) presents a worrisome situation. As of 5-April 2020, the novel

Gene Therapy Companies: Impact on COVID-19

In a recent press release, bluebird bio, one of the leading gene therapy companies, announced that COVID-19 has delayed the EU launch and US filing of the company’s gene therapy candidate Zynteglo (LentiGlobin). The company now expects to dose the first commercial patient with Zynteglo in Germany in the second half of 2020. Earlier, the company had